Aktienanalyse wird geladen …
DVA · NYSE · Medical Care Facilities · USA
174,80 $
| Geschäftsjahr | Umsatz | Nettogewinn | EPS (GAAP) | Aktien (verw., gesamt) | SBC in Stück | Rückkäufe (ca.) | Bruttomarge | Nettomarge | FCF / Aktie | SBC / Aktie | Dividende / Aktie |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025 | 13,64 Mrd. | 746,8 Mio. | 9,84 $ | 75,89 Mio. | 0,8 Mio · 1,1 % | 12,2 Mio · 16,1 % | 32,3 % | 5,5 % | 17,27 $ | 1,84 $ | — |
| 2024 | 12,82 Mrd. | 936,34 Mio. | 10,73 $ | 87,27 Mio. | 0,6 Mio · 0,7 % | 6,5 Mio · 7,4 % | 32,9 % | 7,3 % | 16,80 $ | 1,18 $ | — |
| 2023 | 12,14 Mrd. | 691,54 Mio. | 7,42 $ | 93,18 Mio. | 0,6 Mio · 0,7 % | 3,3 Mio · 3,5 % | 31,5 % | 5,7 % | 16,00 $ | 1,21 $ | — |
| 2022 | 11,61 Mrd. | 560,4 Mio. | 5,85 $ | 95,83 Mio. | 0,5 Mio · 0,6 % | 14,7 Mio · 15,3 % | 29,3 % | 4,8 % | 10,03 $ | 1,00 $ | — |
| 2021 | 11,62 Mrd. | 978,45 Mio. | 8,90 $ | 109,95 Mio. | 0,6 Mio · 0,5 % | 13,3 Mio · 12,1 % | 31,4 % | 8,4 % | 11,73 $ | 0,93 $ | — |
| 2020 | 11,55 Mrd. | 773,64 Mio. | 6,31 $ | 122,62 Mio. | 0,5 Mio · 0,4 % | 31,7 Mio · 25,9 % | 30,8 % | 6,7 % | 10,64 $ | 0,75 $ | — |
| Quartal | Umsatz | Nettogewinn | EPS | Aktien (verw., gesamt) | Nettomarge | FCF / Aktie |
|---|---|---|---|---|---|---|
| Q2 2026 | 3,55 Mrd. | 265,4 Mio. | 4,02 $ | 66,09 Mio. | 7,5 % | 4,85 $ |
| Q1 2026 | 3,42 Mrd. | 197,53 Mio. | 2,87 $ | 68,88 Mio. | 5,8 % | 3,18 $ |
| Q4 2025 | 3,62 Mrd. | 234,22 Mio. | 3,09 $ | 71,26 Mio. | 6,5 % | 5,21 $ |
| Q3 2025 | 3,42 Mrd. | 150,33 Mio. | 2,04 $ | 73,77 Mio. | 4,4 % | 9,16 $ |
| Q2 2025 | 3,38 Mrd. | 199,34 Mio. | 2,58 $ | 77,36 Mio. | 5,9 % | 2,63 $ |
| Q1 2025 | 3,22 Mrd. | 162,92 Mio. | 2,00 $ | — | 5,1 % | — |
| Q4 2024 | 3,29 Mrd. | 259,33 Mio. | 3,42 $ | — | 7,9 % | 4,97 $ |
| Q3 2024 | 3,26 Mrd. | 214,69 Mio. | 2,50 $ | — | 6,6 % | — |
DaVita HealthCare (DVA) Registers a Bigger Fall Than the Market: Important Facts to Note
Is DaVita Stock Underperforming the S&P 500?
DaVita HealthCare (DVA) Advances While Market Declines: Some Information for Investors
DaVita Community Care Report 2025: Empowering Teammates Through Career Development and Education
BofA Adjusts Price Target on DaVita to $180 From $170
DaVita Inc. is a healthcare services company focused on kidney care, with its core business centered on outpatient dialysis for patients living with chronic kidney disease and end-stage renal disease. DaVita provides in-center hemodialysis, peritoneal dialysis, and home dialysis options, along with related clinical support and care coordination services. The company also operates integrated kidney care programs and offers ancillary services that support treatment management and patient care across the kidney health journey. With a large network of dialysis centers in the United States and international markets, DaVita plays a major role in delivering life-sustaining renal care and serving healthcare systems, insurers, and patients who require ongoing treatment.
WebsiteMit einem Konto testest du Glancefield Pro 3 Tage gratis und bewertest DVA und jede andere Aktie unbegrenzt.